ABUS — Arbutus Biopharma Corp

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates ABUS Bullish with a Setup Score of 76, net conviction 43, actionability 136. How the Setup Score works →

Total Setup Score76
Directional BiasBullish
Net Conviction43
Actionability136 (in range)

Key signals behind this score

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.22
Market Cap$641M
Float150.5M
Shares Outstanding153.3M
P/E (Forward)10.25
P/E (TTM)5.29
Price/Sales (TTM)3.53
vs. Analyst Target+27.1% to analyst PT
Profit Margin84.23%
Operating Margin (TTM)-567.16%
Revenue (TTM)$182M
Dividend RateNone
Analyst Target Price$5.36 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $6.9M -$63.7M -$40.6M -$57.8M
2021 $11.0M -$76.2M $11.0M -$71.6M
2022 $39.0M -$69.5M $39.0M -$61.9M
2023 $18.1M -$72.8M $18.1M -$71.0M
2024 $6.2M -$69.9M $6.2M -$68.4M
2025 $14.1M -$33.5M $13.7M -$33.0M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $529,000 -$7.7M
Dec 2025 $1.1M -$3.8M
Mar 2026 $179M $170M
Jun 2026 $1.0M -$5.1M

Ownership & Float

Insider Ownership15.9%
Institutional Ownership66.9%
Short Float12.6%
% of All Funds Holding2.00%
Number of Funds Holding176

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$4.84Near-term / short-term trend
Weekly40-Week SMA$4.48Medium-term trend
Weekly80-Week SMA$4.15Cyclical trend (business cycle)
Weekly200-Week SMA$3.39Secular trend (multi-year)
Monthly10-Month SMA$4.53Near-term monthly trend
Monthly20-Month SMA$4.21Medium-term monthly trend
Monthly40-Month SMA$3.57Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.20 support 1.63x 7 months ago
$3.70 support 1.71x 12 months ago

Historical Earnings Reactions (72 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.28% 0.00% 34.72% 43.21% -11.64%
1 Day 0.33% -0.75% 38.89% 43.21% -21.86%
1 Week -0.38% -1.40% 37.50% 60.42% -23.58%
2 Weeks 0.22% -0.72% 47.22% 54.17% -29.53%
1 Month 2.17% 0.97% 50.70% 62.07% -38.40%

Next earnings: November 12, 2026 (32 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan12.2%57.9%19
Feb4.9%57.9%19
Mar-1.9%52.6%19
Apr-2.0%47.4%19
May8.9%52.6%19
Jun-3.7%42.1%19
Jul12.5%47.4%19
Aug-0.2%35.0%20
Sep4.2%50.0%20
Oct-6.8%26.3%19
Nov0.2%42.1%19
Dec-0.5%21.1%19

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.08% 41.3% 907
Tuesday 0.13% 43.5% 992
Wednesday 0.15% 44.1% 991
Thursday 0.31% 42.0% 971
Friday -0.03% 42.9% 967

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 66.9%

Insider Transactions — Smart Summary

Total insider ownership: 15.9%

12-Month Insider Activity Summary

Total Filings5
Net Value-$363,680
Net Shares Change-9,075,209
% of Float-6.0%
C-Suite Filings2
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Roivant Sciences Ltd. -$44.8M 1 1 sell
Nguyen Tuan Chief Financial Officer -$240,405 1 1 sell
Androski Lindsay President and CEO -$123,275 1 1 sell
Beardsley Robert A -$89,740 1 1 sell
Sawhney Roger -$85,710 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-10-05 – 2026-10-07 5 5 -$45.4M 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-10-07 Nguyen Tuan Chief Financial Officer -$240,405 Transaction at $5.00, now -15.6%
2026-10-07 Androski Lindsay President and CEO -$123,275 Transaction at $5.00, now -15.6%
2026-10-05 Roivant Sciences Ltd. -$44.8M Transaction at $5.00, now -15.6%
2026-10-07 Sawhney Roger -$85,710 Transaction at $5.00, now -15.6%
2026-10-07 Beardsley Robert A -$89,740 Transaction at $5.00, now -15.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Arbutus Biopharma Corp (ABUS) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ABUS on Trend Edge →